Decision Support Systems for Weed Management

Editors: Guillermo R. Chantre, José L. González-Andújar.Weed management Decision Support Systems (DSS) are increasingly important computer-based tools for modern agriculture. Nowadays, extensive agriculture has become highly dependent on external inputs and both economic costs, as well the negative environmental impact of agricultural activities, demands knowledge-based technology for the optimization and protection of non-renewable resources. In this context, weed management strategies should aim to maximize economic profit by preserving and enhancing agricultural systems. Although previous contributions focusing on weed biology and weed management provide valuable insight on many aspects of weed species ecology and practical guides for weed control, no attempts have been made to highlight the forthcoming importance of DSS in weed management. This book is a first attempt to integrate 'concepts and practice' providing a novel guide to the state-of-art of DSS and the future prospects which hopefully would be of interest to higher-level students, academics and professionals in related areas

Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs

Life-threatening `breakthrough' cases of critical COVID-19 are attributed to poor or waning antibody response to the SARS- CoV-2 vaccine in individuals already at risk. Pre-existing autoantibodies (auto-Abs) neutralizing type I IFNs underlie at least 15% of critical COVID-19 pneumonia cases in unvaccinated individuals; however, their contribution to hypoxemic breakthrough cases in vaccinated people remains unknown. Here, we studied a cohort of 48 individuals ( age 20-86 years) who received 2 doses of an mRNA vaccine and developed a breakthrough infection with hypoxemic COVID-19 pneumonia 2 weeks to 4 months later. Antibody levels to the vaccine, neutralization of the virus, and auto- Abs to type I IFNs were measured in the plasma. Forty-two individuals had no known deficiency of B cell immunity and a normal antibody response to the vaccine. Among them, ten (24%) had auto-Abs neutralizing type I IFNs (aged 43-86 years). Eight of these ten patients had auto-Abs neutralizing both IFN-a2 and IFN-., while two neutralized IFN-omega only. No patient neutralized IFN-ss. Seven neutralized 10 ng/mL of type I IFNs, and three 100 pg/mL only. Seven patients neutralized SARS-CoV-2 D614G and the Delta variant (B.1.617.2) efficiently, while one patient neutralized Delta slightly less efficiently. Two of the three patients neutralizing only 100 pg/mL of type I IFNs neutralized both D61G and Delta less efficiently. Despite two mRNA vaccine inoculations and the presence of circulating antibodies capable of neutralizing SARS-CoV-2, auto-Abs neutralizing type I IFNs may underlie a significant proportion of hypoxemic COVID-19 pneumonia cases, highlighting the importance of this particularly vulnerable population